Galcanezumab: Empowering migraineurs on the journey to migraine-freedom

Galcanezumab (Emgality^®, DKSH Singapore) was developed to target calcitonin gene-related peptide (CGRP) to prevent migraine._1-3 At the symposium to mark the launch of Emgality^® in Singapore on 23 January 2021 chaired by Dr Jonathan Ong, Dr Patricia Pozo-Rosich provided an overview of the current clinical and real-world evidence supporting the use of galcanezumab; a panel discussion led by Dr Ho King Hee and Dr Zhao Yi Jing also highlighted local headache specialists’ experience in the use of CGRP monoclonal antibodies (mAbs) in the treatment of patients with migraine.